Development of a Cell-Based Assay to Assess Binding of the proNGF Prodomain to Sortilin

被引:2
|
作者
Malik, Ibrahim [1 ]
Christensen, Soren [1 ]
Stavenhagen, Jeffrey B. [1 ]
Dietz, Gunnar P. H. [1 ]
机构
[1] H Lundbeck & Co AS, Dept Neurodegenerat, Ottiliavej 9, DK-2500 Valby, Denmark
关键词
Cellular assay; Cell-based assay; SORLA family; Nerve growth factor (NGF); Brain-derived neurotrophic factor (BDNF); Apoptosis; RECEPTOR SORTILIN; NEUROTENSIN; IDENTIFICATION; PROTEIN;
D O I
10.1007/s10571-017-0558-1
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Sortilin was first identified based on its activity as part of intracellular protein sorting machinery. Recently, it was discovered that sortilin also acts as a cell surface receptor for the propeptide form of nerve growth factor (proNGF), progranulin, and neurotensin. The interaction of sortilin to these neurotrophic ligands is linked to diseases of the nervous system that lead to neurodegeneration and neuropathic pain. Blocking of the interaction of sortilin to these ligands may prevent or slow the progress of these nervous system disorders. In vitro screening assays for blocking compounds or peptides are part of the standard set of tools for drug discovery. However, assays for sortilin biology are not readily available to determine if the selected blocking agent inhibits sortilin activity on the surface of cells. We have developed a sortilin specific cell based assay to identify compounds that specifically block interaction between sortilin and proNGF prodomain. The assay system records both the presence of sortilin on the cell surface and the interaction with the pro domain of NGF. Fluorescent images of the sortilin expressing cells are analyzed for the presence of pro domain of NGF. Sortilin-positive and sortilin-negative cells within one well are concomitantly and automatically analyzed. Sortilin-pro domain interaction can be blocked dose dependently by neurotensin and synthetic compounds. The assay will facilitate the discovery of entities interfering with the binding of sortilin to the NGF pro domain. This assay can be modified to screen for inhibitors of the binding of ligands to other complex cell surface receptors.
引用
收藏
页码:827 / 840
页数:14
相关论文
共 50 条
  • [21] Development of a potency assay for CD34+ cell-based therapy
    Aries, Anne
    Vignon, Christine
    Zanetti, Celine
    Goubaud, Aurelien
    Cormier, Arthur
    Diederichs, Anne
    Lahlil, Rachid
    Henon, Philippe
    Garitaonandia, Ibon
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [22] Development of a Cell-Based Assay for Measuring Base Excision Repair Responses
    Tyler Golato
    Boris Brenerman
    Daniel R. McNeill
    Jianfeng Li
    Robert W. Sobol
    David M. Wilson
    Scientific Reports, 7
  • [23] DEVELOPMENT OF A GPR23 CELL-BASED β-LACTAMASE REPORTER ASSAY
    Lee, Paul H.
    Hanson, Bonnie J.
    METHODS IN ENZYMOLOGY, VOLUME 485: CONSTITUTIVE ACTIVITY IN RECEPTORS AND OTHER PROTEINS, PART B, 2010, 485 : 349 - 368
  • [24] Improving AAV in vitro transducibility for cell-based potency assay development
    Girona, G. Estrada
    Georgiadis, A.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A193 - A193
  • [25] Development of a stem cell-based reporter assay for in vitro DART assessment
    Racz, Peter
    Ottenheijm, Roger
    Derr, Remco
    Hendriks, Giel
    TOXICOLOGY LETTERS, 2017, 280 : S122 - S123
  • [26] Development of a potency assay for CD34+ cell-based therapy
    Anne Aries
    Christine Vignon
    Céline Zanetti
    Aurélien Goubaud
    Arthur Cormier
    Anne Diederichs
    Rachid Lahlil
    Philippe Hénon
    Ibon Garitaonandia
    Scientific Reports, 13
  • [27] Development of a Cell-Based Assay for Measuring Base Excision Repair Responses
    Golato, Tyler
    Brenerman, Boris
    McNeill, Daniel R.
    Li, Jianfeng
    Sobol, Robert W.
    Wilson, David M., III
    SCIENTIFIC REPORTS, 2017, 7
  • [28] The development of a stem cell-based assay for quality control testing in IVF
    Adjirackor, N.
    Beckitt, T.
    Fowler, K.
    Harvey, S.
    HUMAN REPRODUCTION, 2020, 35 : 1506 - 1507
  • [29] Development of a Stem Cell-Based Reporter Assay for In Vitro DART Assessment
    Racz, P., I
    Brandsma, I
    Derr, R.
    Hendriks, G.
    BIRTH DEFECTS RESEARCH, 2018, 110 (09): : 793 - 793
  • [30] Development of a cell-based target engagement assay for pyruvate dehydrogenase kinase
    Gough, Mya D.
    Robers, Matthew B.
    Corona, Cesear R.
    Mehta, Ranjit K.
    Nyati, Mukesh K.
    Toogood, Peter L.
    SLAS DISCOVERY, 2025, 32